Free Trial

Dimensional Fund Advisors LP Reduces Stock Position in MacroGenics, Inc. (NASDAQ:MGNX)

MacroGenics logo with Medical background

Dimensional Fund Advisors LP trimmed its holdings in MacroGenics, Inc. (NASDAQ:MGNX - Free Report) by 14.5% during the second quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 898,497 shares of the biopharmaceutical company's stock after selling 152,762 shares during the quarter. Dimensional Fund Advisors LP owned about 1.43% of MacroGenics worth $3,818,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

A number of other hedge funds and other institutional investors also recently made changes to their positions in MGNX. Acadian Asset Management LLC lifted its stake in MacroGenics by 23.8% in the second quarter. Acadian Asset Management LLC now owns 586,079 shares of the biopharmaceutical company's stock valued at $2,489,000 after buying an additional 112,666 shares during the period. Principal Financial Group Inc. lifted its position in shares of MacroGenics by 1.1% during the 2nd quarter. Principal Financial Group Inc. now owns 348,421 shares of the biopharmaceutical company's stock valued at $1,481,000 after acquiring an additional 3,818 shares during the period. Panagora Asset Management Inc. boosted its stake in MacroGenics by 60.0% during the second quarter. Panagora Asset Management Inc. now owns 741,490 shares of the biopharmaceutical company's stock worth $3,151,000 after acquiring an additional 278,060 shares in the last quarter. Zurcher Kantonalbank Zurich Cantonalbank grew its holdings in MacroGenics by 300.6% in the second quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 16,072 shares of the biopharmaceutical company's stock worth $68,000 after purchasing an additional 12,060 shares during the period. Finally, Bank of New York Mellon Corp increased its stake in MacroGenics by 4.9% in the second quarter. Bank of New York Mellon Corp now owns 261,944 shares of the biopharmaceutical company's stock valued at $1,113,000 after purchasing an additional 12,237 shares in the last quarter. 96.89% of the stock is owned by institutional investors and hedge funds.

MacroGenics Price Performance

Shares of NASDAQ MGNX traded up $0.09 during mid-day trading on Thursday, reaching $3.74. 554,633 shares of the company's stock were exchanged, compared to its average volume of 1,566,470. The firm has a market capitalization of $234.25 million, a price-to-earnings ratio of -9.51 and a beta of 2.08. The firm has a 50-day moving average price of $3.44 and a two-hundred day moving average price of $6.83. MacroGenics, Inc. has a 52 week low of $2.95 and a 52 week high of $21.88.

MacroGenics (NASDAQ:MGNX - Get Free Report) last released its earnings results on Tuesday, August 6th. The biopharmaceutical company reported ($0.89) earnings per share for the quarter, missing analysts' consensus estimates of ($0.47) by ($0.42). MacroGenics had a negative net margin of 332.47% and a negative return on equity of 146.01%. The company had revenue of $10.80 million during the quarter, compared to analysts' expectations of $24.14 million. As a group, sell-side analysts forecast that MacroGenics, Inc. will post -1.72 EPS for the current fiscal year.

Analysts Set New Price Targets

MGNX has been the subject of a number of research analyst reports. B. Riley lowered MacroGenics from a "buy" rating to a "neutral" rating and decreased their target price for the company from $18.00 to $5.00 in a research report on Wednesday, July 31st. JMP Securities cut their target price on MacroGenics from $16.00 to $8.00 and set a "market outperform" rating on the stock in a report on Wednesday, July 31st. Barclays reduced their price target on shares of MacroGenics from $14.00 to $9.00 and set an "overweight" rating for the company in a research report on Monday, July 29th. StockNews.com downgraded shares of MacroGenics from a "hold" rating to a "sell" rating in a report on Thursday, August 8th. Finally, BTIG Research cut shares of MacroGenics from a "buy" rating to a "neutral" rating in a report on Thursday, August 1st. One investment analyst has rated the stock with a sell rating, seven have given a hold rating, three have given a buy rating and one has assigned a strong buy rating to the stock. According to data from MarketBeat.com, MacroGenics presently has a consensus rating of "Hold" and a consensus price target of $8.11.

View Our Latest Stock Analysis on MGNX

MacroGenics Profile

(Free Report)

MacroGenics, Inc, a biopharmaceutical company, develops, manufactures, and commercializes antibody-based therapeutics to treat cancer in the United States. Its approved product is MARGENZA (margetuximab-cmkb), a human epidermal growth factor receptor 2 (HER2) receptor antagonist indicated, in combination with chemotherapy, for the treatment of adult patients with metastatic HER2-positive breast cancer who have received two or more prior anti-HER2 regimens.

Featured Stories

Institutional Ownership by Quarter for MacroGenics (NASDAQ:MGNX)

Should you invest $1,000 in MacroGenics right now?

Before you consider MacroGenics, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and MacroGenics wasn't on the list.

While MacroGenics currently has a "Hold" rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here

7 Energy Stocks to Buy and Hold Forever Cover

Do you expect the global demand for energy to shrink?! If not, it's time to take a look at how energy stocks can play a part in your portfolio.

Get This Free Report
Like this article? Share it with a colleague.

Featured Articles and Offers

Recent Videos

Post-Election Chaos or Opportunity? Prepare Your Investments
Strong Markets Meet Rising Volatility—Are Your Investments Safe?
Analysts Bullish on AI-Powered Healthcare: Intuitive Surgical’s 30% Upside

Stock Lists

All Stock Lists

Investing Tools

Calendars and Tools

Search Headlines